Literature DB >> 9311601

Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells.

M K Nolan1, L Jankowska, M Prisco, S Xu, M A Guvakova, E Surmacz.   

Abstract

Several polypeptide growth factors stimulate breast cancer growth and may be involved in tumor progression. However, the relative importance of diverse growth factor signaling pathways in the development and maintenance of the neoplastic phenotype is largely unknown. The activation of such growth factor receptors as the insulin-like growth factor I receptor (IGF-I R), erbB-type receptors (erbB Rs) and FGF receptors (FGF Rs) controls the phenotype of a model breast cancer cell line MCF-7. To evaluate the function of 2 post-receptor signaling molecules, insulin receptor substrate-1 (IRS-1) (a major substrate of the IGF-IR) and SHC (a common substrate of tyrosine kinase receptors), we developed several MCF-7-derived cell clones in which the synthesis of either IRS-1 or SHC was blocked by antisense RNA. In MCF-7 cells, down-regulation of IRS-1 by 80-85% strongly suppressed anchorage-dependent and -independent growth and induced apoptotic cell death under growth factor- and estrogen-reduced conditions. The reduction of SHC levels by approximately 50% resulted in the inhibition of monolayer and anchorage-independent growth but did not decrease cell survival. Importantly, cell aggregation and the ability of cells to survive on the extracellular matrix were inhibited in MCF-7/anti-SHC clones, but not in MCF-7/anti-IRS-1 clones. Cell motility toward IGF was not attenuated in any of the tested cell lines, but motility toward EGF was decreased in MCF-7/anti-SHC clones. Our results suggest that in MCF-7 cells: 1) both IRS-1 and SHC are implicated in the control of monolayer and anchorage-independent growth; 2) IRS-1 is critical to support cell survival; 3) SHC is involved in EGF-dependent motility; and 4) normal levels of SHC, but not IRS-1, are necessary for the formation and maintenance of cell-cell interactions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9311601     DOI: 10.1002/(sici)1097-0215(19970904)72:5<828::aid-ijc20>3.0.co;2-3

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

1.  Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion.

Authors:  L M Shaw
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

2.  The R-Ras GTPase mediates cross talk between estrogen and insulin signaling in breast cancer cells.

Authors:  Yi Yu; Yansheng Hao; Larry A Feig
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

3.  Expression of nuclear insulin receptor substrate 1 in breast cancer.

Authors:  Diego Sisci; Catia Morelli; Cecilia Garofalo; Francesco Romeo; Lucio Morabito; Filomena Casaburi; Emilia Middea; Sandra Cascio; Elvira Brunelli; Sebastiano Andò; Eva Surmacz
Journal:  J Clin Pathol       Date:  2006-08-01       Impact factor: 3.411

4.  Type 1 Insulin-Like Growth Factor Receptor/Insulin Receptor Substrate 1 Signaling Confers Pathogenic Activity on Breast Tumor Cells Lacking REST.

Authors:  Kassondra Meyer; Brittany Albaugh; Barry Schoenike; Avtar Roopra
Journal:  Mol Cell Biol       Date:  2015-06-22       Impact factor: 4.272

5.  Identification of a Novel Invasion-Promoting Region in Insulin Receptor Substrate 2.

Authors:  Jose Mercado-Matos; Jenny Janusis; Sha Zhu; Samuel S Chen; Leslie M Shaw
Journal:  Mol Cell Biol       Date:  2018-06-28       Impact factor: 4.272

Review 6.  Function of the IGF-I receptor in breast cancer.

Authors:  E Surmacz
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

7.  ERα and ERβ expression in correlation with Ki-67, Bcl-2 and Bak in primary tumors and lymph node metastases of breast cancer: The effect of pre-operative chemotherapy.

Authors:  Luiza Kanczuga-Koda; Mariusz Koda; Jakub Tomaszewski; Katarzyna Jarzabek; Joanna Lotowska; Marek Baltaziak; Urszula Sulkowska; Maria Sobaniec-Lotowska; Stanisław Sulkowski
Journal:  Oncol Lett       Date:  2010-09-23       Impact factor: 2.967

8.  Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis.

Authors:  Zhefu Ma; Shannon L Gibson; Maura A Byrne; Junran Zhang; Morris F White; Leslie M Shaw
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

9.  Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.

Authors:  Ilenia Migliaccio; Meng-Fen Wu; Carolina Gutierrez; Luca Malorni; Syed K Mohsin; D Craig Allred; Susan G Hilsenbeck; C Kent Osborne; Heidi Weiss; Adrian V Lee
Journal:  Breast Cancer Res Treat       Date:  2009-11-19       Impact factor: 4.872

10.  Expression and function of the insulin receptor substrate proteins in cancer.

Authors:  Katerina Mardilovich; Shannon L Pankratz; Leslie M Shaw
Journal:  Cell Commun Signal       Date:  2009-06-17       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.